Outcome of Graves' thyrotoxicosis after antithyroid drug treatment. 1995

S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.

To investigate the outcome of Graves' thyrotoxicosis after antithyroid drug management, data from 81 patients, treated in Chang Gung Memorial Hospital at Taipei and Linkou from October 1981 to March 1990, were analyzed. The gender ratio of female to male was 59:22. The mean age of onset was 33.1 +/- 10.5(15-60) year-old. All the patients were treated with antithyroid drug (Thionamide group) for a duration of 11 to 63 months (mean +/- SD = 28.1 +/- 9.8 months). Forty of 81 patients (49.4%) were remained remission after up to 2 years of follow-up. Those patients relapse usually occurred within 2 years after discontinuation of treatment (34/41), and only one exceptional case relapsed after 3 years. Three conditions affected the relapse rate. Patients with larger goiter (grade II-III) and shorter duration of treatment (< 23 months) had a higher relapse rate than those-with smaller goiter (grade O-I) [29/46 vs. 12/35; chi 2 = 6.576, p = 0.010; p = 0.015 in stepwise logistic regression (LR)] and longer duration of treatment (> or = 23 months) (15/20 vs. 26/61; chi 2 = 6.316, p = 0.012; p = 0.020 in LR). Patients with higher pre-treated serum triiodothyronine (T3) level (T3 > or = 300 ng/dl) had a higher relapse rate than those with lower T3 level (T3 < 300 ng/dl) in univariate analysis (30/50 vs. 11/31, chi 2 = 4.601, p = 0.032), but no significant difference by LR (P = 0.094). Other clinical parameters including age, sex, past history, family history, thyroxine (T4) level, T3/T4 ratio, thyroid autoantibodies, staging of ophthalmopathy, responsiveness to thyrotropin-releasing hormone stimulation test at the end of treatment, and whether combined treatment with thyroxine had no significant difference between the relapse and remission groups. These data suggest: (a) patients with larger goiter (grade II-III had higher relapse rate; (b) most of the recurrent thyrotoxicosis patients relapsed within two years after drug withdrawal; (c) continuing treatment for more than twenty-three months produces better outcome; (d) patients with Graves' thyrotoxicosis should be followed up for at least three years after withdrawal of antithyroid drug.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
September 1998, Journal of the Formosan Medical Association = Taiwan yi zhi,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
January 2008, Thyroid : official journal of the American Thyroid Association,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
June 2021, Endocrinology and metabolism (Seoul, Korea),
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
February 1988, The Quarterly journal of medicine,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
July 1969, British medical journal,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
June 2010, Clinical endocrinology,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
April 1999, Zeitschrift fur arztliche Fortbildung und Qualitatssicherung,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
August 1999, Clinical and investigative medicine. Medecine clinique et experimentale,
S C Chiou, and H S Houng, and K L Li, and T C Ghang, and S K Lo, and R H Sun, and Y Y Huang, and B R Hsu, and J D Lin, and B Y Hunang
July 2006, Praxis,
Copied contents to your clipboard!